



1652  
Docket No. ORT-1417

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Anne M. Fourie, et al.

Serial No. : 10/050,200

Art Unit: 1652

Filed : January 16, 2002

Examiner: Walicka

For : Aggrecanase-1 and -2 Peptide Substrates  
and Methods

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Laura A. Donnelly

(Date of Deposit)

August 28, 2003

Laura A. Donnelly  
(Name of applicant, assignee, or Registered Representative)

Laura A. Donnelly

(Signature)

August 28, 2003

(Date of Signature)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on June 14, 2002.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with  the first or  second After Final Submission, therefore:

- Statement in Accordance with §1.97(e)  
(attached); or
- Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

Statement in Accordance with §1.97(e)  
(attached); or

Please charge Deposit Account No. 10-  
0750/ / the fee of \$180.00 as set forth  
in §1.17(p).

In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not

enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

There are no listed references which are not in the English language.

The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed .

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT-1417/LAD. This form is submitted in triplicate.

Respectfully submitted,

Laura A. Donnelly  
Laura A. Donnelly  
Reg. No. 38,435  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1729  
DATED: August 28, 2003



Docket No. ORT-1417

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Anne M. Fourie, et al.

Serial No. : 10/050,200 Art Unit: 1652

Filed : January 16, 2002 Examiner: Walicka

For : Aggrecanase-1 and -2 Peptide Substrates  
and Methods

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Laura A. Donnelly

August 28, 2003

(Date of Deposit)

Laura A. Donnelly  
(Name of applicant, assignee, or Registered Representative)

Laura A. Donnelly

(Signature)

August 28, 2003

(Date of Signature)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. §1.97(e)

In accordance with 37 C.F.R. §1.97(e), certification is hereby  
made that:

Each item of information contained in the information  
disclosure statement was first cited in any communication from a  
foreign patent office in a counterpart foreign application not more  
than three months prior to the filing of the Information Disclosure  
Statement; or

No item of information contained in the Information  
Disclosure Statement was cited in a communication from a foreign  
patent office in a counterpart foreign application, and, to the

knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

*Laura A. Donnelly*

Laura A. Donnelly  
Reg. No. 38,435  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1729  
DATED: August 28, 2003



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

<b>Application Number</b>	10/050,200
<b>Filing Date</b>	January 16, 2002
<b>First Named Inventor</b>	Anne M. Fourie
<b>Group Art Unit</b>	1652
<b>Examiner Name</b>	Walicka
<b>Attorney Docket Number</b>	ORT-1417

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature \_\_\_\_\_ Date Considered \_\_\_\_\_

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Indicate to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22312-1450.



SUBMISSION UNDER MPEP 609 D

Page 1 of 1

 <b>SUBMISSION UNDER MPEP 609 D</b>		<b>Application Number</b> 10/050,200 <b>Filing Date</b> January 16, 2002 <b>First Named Inventor</b> Anne M. Fouri <b>Group Art Unit</b> 1652 <b>Examiner Name</b> Walicka <b>Attorney Docket Number</b> ORT-1417
---	--	--

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Serial No. 10/050,200 Docket No. ORT-1417 By: LAD  
Application of: Anne M. Fournel et al Mailed: August 28, 2003  
Entitled: Aggrecanase-1 and -2 Peptide substrates  
and Methods

THE FOLLOWING HAS BEEN RECEIVED IN THE U.S. PATENT OFFICE ON THE DATE STAMPED HEREON:

Oath or Declaration  
 Assignment  
 Charge to Deposit Account 10-0750  
 Amendment  
 Extension of Time  
 Issue Fee Transmittal  
 PCT Filing \_\_\_\_\_

IDS-Form 1449

Drawings        sheets

MPEP 609/ \_\_\_\_\_

Notice of Appeal

Brief

Priority Document

Status Inquiry

Sequence Listings/Diskette

Biological Deposit Declaration

Other Supplemental Information

Disclosure Statement

Statement under 37 CFR 1.97(e)

Copies of US and Foreign Patents  
and other Prior Art